In the DIO mouse model, ISM6200 demonstrated a good weight loss effect, mainly reducing fat while better retaining muscle mass. (IMAGE)

InSilico Medicine

In the DIO mouse model, ISM6200 demonstrated a good weight loss effect, mainly reducing fat while better retaining muscle mass.

Caption

After 28 days of administration, compared with the control group, ISM6200 monotherapy achieved significant weight loss, with a relative weight reduction of 8.8% from the baseline. When ISM6200 was combined with Semaglutide, the weight loss effect was further enhanced, reaching 23.8% within the same administration period, while the DIO control group gained 2.4% in weight. The above data provided strong support for subsequent clinical development.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.